CSIMarket
 
Immutep Limited  (IMMP)
Other Ticker:  
 

Immutep Limited

Business Description


Immutep Limited is an Australian-based biotechnology company that specializes in developing immunotherapeutic treatments for cancer and autoimmune diseases. The company was founded in 2001 and is listed on the Australian Securities Exchange (ASX: IMM) and the NASDAQ Global Market (NASDAQ: IMMP).

Immutep focuses on harnessing the power of the immune system to combat diseases. Their proprietary technology platform, called IMP321, is a soluble LAG-3 (lymphocyte activation gene-3) fusion protein. LAG-3 is a cell surface molecule that plays a crucial role in regulating T cells, which are central to immune responses. By targeting LAG-3, Immutep aims to enhance T cell responses and promote an immune-mediated attack on cancer cells or modulate immune responses in autoimmune diseases.

The company*s lead product candidate, eftilagimod alpha (efti), is a soluble LAG-3 protein that is being developed for the treatment of various cancers. It is designed to bind to LAG-3 receptors on antigen-presenting cells (APCs), stimulating the immune response against cancer cells. Efti is being evaluated in multiple clinical trials in different cancer indications, such as breast cancer, head and neck cancer, and metastatic melanoma.

Immutep also has other programs in its pipeline. IMP731 is a preclinical product candidate targeting autoimmune diseases, particularly multiple sclerosis. It is designed to block LAG-3 receptors and regulate immune responses in autoimmune conditions. The company is conducting extensive research to understand the potential of IMP731 in various autoimmune diseases.

Furthermore, Immutep has collaborations and partnerships with several pharmaceutical companies and research institutions. These collaborations provide additional resources, expertise, and funding to advance their product candidates and explore new opportunities in the field of immunotherapy. Notable partners include Merck KGaA and Pfizer.

Immutep has a highly skilled team of scientists, researchers, and industry professionals dedicated to the development of novel immunotherapeutic treatments. The company*s expertise lies in immunology, oncology, and drug development, allowing them to leverage the latest advancements in these fields to address unmet medical needs.

In terms of financials, Immutep has raised capital through public offerings, private placements, and strategic partnerships. The company also receives grants and funding from government organizations and research institutions to support its research and development efforts.

Overall, Immutep Limited is a pioneering biotechnology company focused on utilizing the immune system to develop innovative treatments for cancer and autoimmune diseases. Through its proprietary technology and partnerships, the company aims to make significant advancements in the field of immunotherapy and improve patient outcomes.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com